Eric J. Avery

725 total citations · 1 hit paper
17 papers, 446 citations indexed

About

Eric J. Avery is a scholar working on Genetics, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Eric J. Avery has authored 17 papers receiving a total of 446 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Genetics, 7 papers in Pathology and Forensic Medicine and 6 papers in Hematology. Recurrent topics in Eric J. Avery's work include Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Eric J. Avery is often cited by papers focused on Chronic Lymphocytic Leukemia Research (10 papers), Lymphoma Diagnosis and Treatment (6 papers) and Chronic Myeloid Leukemia Treatments (6 papers). Eric J. Avery collaborates with scholars based in United States, South Korea and Spain. Eric J. Avery's co-authors include Árpád Illés, Martin Šimkovič, Sean Dolan, Abraham Jacob, Andrzej Pluta, Paolo Ghia, Małgorzata Wach, Daniel Lysák, Wojciech Jurczak and Javier de la Serna and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Eric J. Avery

16 papers receiving 439 citations

Hit Papers

ASCEND: Phase III, Randomized Trial of Acalabrutinib Vers... 2020 2026 2022 2024 2020 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
    2020 252 citations Paolo Ghia, Andrzej Pluta et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric J. Avery United States 8 347 280 121 111 76 17 446
Gerry Ann Houston United States 8 229 0.7× 246 0.9× 26 0.2× 117 1.1× 265 3.5× 15 629
Yoonjin Cho United States 8 378 1.1× 327 1.2× 83 0.7× 98 0.9× 141 1.9× 16 480
Mary Browning United States 9 329 0.9× 322 1.1× 94 0.8× 197 1.8× 78 1.0× 17 461
Julia von Tresckow Germany 9 333 1.0× 303 1.1× 92 0.8× 128 1.2× 49 0.6× 35 391
Ana Isabel Manzanal Martínez Spain 12 56 0.2× 303 1.1× 26 0.2× 53 0.5× 183 2.4× 25 463
Ilya Zyuzgin Russia 3 323 0.9× 301 1.1× 59 0.5× 149 1.3× 50 0.7× 7 364
Guillem Clot Spain 12 190 0.5× 234 0.8× 19 0.2× 105 0.9× 140 1.8× 23 491
Moiseev Si Russia 4 393 1.1× 348 1.2× 101 0.8× 181 1.6× 54 0.7× 14 452
R. F. Bezares Argentina 3 516 1.5× 438 1.6× 97 0.8× 250 2.3× 72 0.9× 5 555
Richard F Schlenk Germany 5 312 0.9× 252 0.9× 62 0.5× 159 1.4× 56 0.7× 5 368

Countries citing papers authored by Eric J. Avery

Since Specialization
Citations

This map shows the geographic impact of Eric J. Avery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric J. Avery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric J. Avery more than expected).

Fields of papers citing papers by Eric J. Avery

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric J. Avery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric J. Avery. The network helps show where Eric J. Avery may publish in the future.

Co-authorship network of co-authors of Eric J. Avery

This figure shows the co-authorship network connecting the top 25 collaborators of Eric J. Avery. A scholar is included among the top collaborators of Eric J. Avery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric J. Avery. Eric J. Avery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2022). Acalabrutinib Versus Investigator’s Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results. HemaSphere. 6(12). e801–e801. 65 indexed citations
2.
Ghia, Paolo, Małgorzata Wach, Daniel Lysák, et al.. (2022). P668: ACALABRUTINIB VS RITUXIMAB PLUS IDELALISIB OR BENDAMUSTINE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA: ASCEND RESULTS AT ~4 YEARS OF FOLLOW-UP. HemaSphere. 6. 566–567. 1 indexed citations
3.
Jurczak, Wojciech, Andrzej Pluta, Małgorzata Wach, et al.. (2022). Acalabrutinib versus rituximab plus idelalisib or bendamustine in relapsed/refractory chronic lymphocytic leukemia: ASCEND results at 4 years of follow-up.. Journal of Clinical Oncology. 40(16_suppl). 7538–7538. 3 indexed citations
4.
Jurczak, Wojciech, Andrzej Pluta, Małgorzata Wach, et al.. (2021). Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood. 138(Supplement 1). 393–393. 15 indexed citations
5.
Catenacci, Daniel V.T., Byoung Yong Shim, S.T. Kim, et al.. (2021). 1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A. Annals of Oncology. 32. S1043–S1044. 13 indexed citations
6.
Shirani, Afsaneh, Scott R. Dalton, Eric J. Avery, et al.. (2021). Lymphomatoid papulosis in a patient treated with glatiramer acetate and the glatiramoid Glatopa for multiple sclerosis: A case report. SHILAP Revista de lepidopterología. 13. 2669581016–2669581016.
7.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology. 38(25). 2849–2861. 252 indexed citations breakdown →
8.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results. Clinical Lymphoma Myeloma & Leukemia. 20. S220–S221. 1 indexed citations
9.
Avery, Eric J., Benjamin D. Byers, Jennifer J. McIntosh, et al.. (2020). Thrombotic thrombocytopenic purpura masquerading as preclampsia with severe features at 13 weeks' gestation. American Journal of Hematology. 95(10). 1216–1220. 6 indexed citations
10.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2020). Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.. Journal of Clinical Oncology. 38(15_suppl). 8015–8015. 5 indexed citations
11.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2019). Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. Clinical Lymphoma Myeloma & Leukemia. 19. S280–S281. 1 indexed citations
12.
13.
Ghia, Paolo, Andrzej Pluta, Małgorzata Wach, et al.. (2019). Acalabrutinib vs Rituximab Plus Idelalisib (IdR) or Bendamustine (BR) by Investigator Choice in Relapsed/Refractory (RR) Chronic Lymphocytic Leukemia: Phase 3 ASCEND Study. Hematological Oncology. 37(S2). 86–87. 21 indexed citations
14.
15.
Avery, Eric J., Anne Kessinger, & Apar Kishor Ganti. (2009). Therapeutic options for elderly patients with advanced non-small cell lung cancer. Cancer Treatment Reviews. 35(4). 340–344. 18 indexed citations
16.
Bockting, Walter & Eric J. Avery. (2006). Transgender Health and HIV Prevention: Needs Assessment Studies from Transgender Communities Across the United States. 35 indexed citations
17.
Bockting, Walter & Eric J. Avery. (2005). Introduction. International Journal of Transgenderism. 8(2-3). 1–3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerry Ann Houston Breakdown of academic impact, for papers by Yoonjin Cho Breakdown of academic impact, for papers by Mary Browning Breakdown of academic impact, for papers by Julia von Tresckow Breakdown of academic impact, for papers by Ana Isabel Manzanal Martínez Breakdown of academic impact, for papers by Ilya Zyuzgin Breakdown of academic impact, for papers by Guillem Clot Breakdown of academic impact, for papers by Moiseev Si Breakdown of academic impact, for papers by R. F. Bezares Breakdown of academic impact, for papers by Richard F Schlenk
Rankless by CCL
2026